26th AGM Approves Treasury Stock Acquisition and Interim Dividend; 27Q1 Net Profit Down 26% YoY
-
At the 26th AGM on March 26, 2026, resolutions for treasury stock acquisition and interim dividend were passed (shareholder proposals).
-
27Q1 consolidated: Sales ₩21.50B (down 5.9% YoY), operating profit ₩763M, net profit ₩565M (down 26.2% YoY), EPS ₩66.
-
Total assets ₩79.46B, liabilities ₩24.37B, equity ₩55.10B (equity ratio 69.3%).
-
Foreign exchange loss of ₩406M occurred (USD/EUR fluctuations); foreign currency borrowings ₩1.63B.
-
R&D expenses ₩230M (1.07% of sales), 3 government projects in progress.
-
Cash and cash equivalents ₩8.74B, short-term financial instruments ₩17.77B.
-
Total borrowings ₩16.29B (current ₩11.71B, non-current ₩4.58B); collateral provided on assets.
-
Major shareholder: Lee Chan-ho 28.09%, others 71.45%.
KOSDAQ Filing Information
-
Filing: Quarterly Report (2026.03)
-
Company: GeneBioTech (086060)
-
Submission: GeneBioTech Co., Ltd.
-
Receipt: 05-14-2026